Optineurin Negatively Regulates Osteoclast Differentiation by Modulating NF-κB and Interferon Signaling: Implications for Paget's Disease

Cell Reports

Volumn 13, Issue 6, 2015, Pages 1096-1102

  Obaid, Rami ^a   Wani, Sachin E ^a   Azfer, Asim ^a   Hurd, Toby ^a   Jones, Ruth ^b   Cohen, Philip ^b   Ralston, Stuart H ^a   Albagha, Omar M E ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON; OPTINEURIN; OSTEOCLAST DIFFERENTIATION FACTOR; EYE PROTEIN; OPTN PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE TURNOVER; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE EXPRESSION; GENE LOCUS; GENETIC PREDISPOSITION; HUMAN; HUMAN CELL; LOSS OF FUNCTION MUTATION; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; OPTINEURIN GENE; OSTEOCLAST; OSTEOCLAST ACTIVITY; OSTEOLYSIS; PAGET BONE DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; ANIMAL; BONE DEVELOPMENT; CELL CULTURE; CYTOLOGY; GENETICS; METABOLISM;

ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; EYE PROTEINS; INTERFERON-BETA; MICE; NF-KAPPA B; OSTEITIS DEFORMANS; OSTEOCLASTS; OSTEOGENESIS; RANK LIGAND; SIGNAL TRANSDUCTION;

EID: 84946836881     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2015.09.071     Document Type: Article

References (21)

1. Albagha O.M., Visconti M.R., Alonso N., Langston A.L., Cundy T., Dargie R., Dunlop M.G., Fraser W.D., Hooper M.J., Isaia G., et al. Genome-wide association study identifies variants at CSF1, OPTN and TNFRSF11A as genetic risk factors for Paget's disease of bone. Nat. Genet. 2010, 42:520-524.
2. Albagha O.M., Wani S.E., Visconti M.R., Alonso N., Goodman K., Brandi M.L., Cundy T., Chung P.Y., Dargie R., Devogelaer J.P., et al. Genome-wide association identifies three new susceptibility loci for Paget's disease of bone. Nat. Genet. 2011, 43:685-689. Genetic Determinants of Paget's Disease (GDPD) Consortium.
3. Cavey J.R., Ralston S.H., Sheppard P.W., Ciani B., Gallagher T.R., Long J.E., Searle M.S., Layfield R. Loss of ubiquitin binding is a unifying mechanism by which mutations of SQSTM1 cause Paget's disease of bone. Calcif. Tissue Int. 2006, 78:271-277.
4. Daroszewska A., van 't Hof R.J., Rojas J.A., Layfield R., Landao-Basonga E., Rose L., Rose K., Ralston S.H. A point mutation in the ubiquitin-associated domain of SQSMT1 is sufficient to cause a Paget's disease-like disorder in mice. Hum. Mol. Genet. 2011, 20:2734-2744.
5. Dempster D.W., Compston J.E., Drezner M.K., Glorieux F.H., Kanis J.A., Malluche H., Meunier P.J., Ott S.M., Recker R.R., Parfitt A.M. Standardized nomenclature, symbols, and units for bone histomorphometry: a 2012 update of the report of the ASBMR Histomorphometry Nomenclature Committee. J. Bone Miner. Res. 2013, 28:2-17.
6. Erben R.G., Glösmann M. Histomorphometry in rodents. Methods Mol. Biol. 2012, 816:279-303.
7. Gleason C.E., Ordureau A., Gourlay R., Arthur J.S., Cohen P. Polyubiquitin binding to optineurin is required for optimal activation of TANK-binding kinase 1 and production of interferon β. J. Biol. Chem. 2011, 286:35663-35674.
8. Hayashi T., Kaneda T., Toyama Y., Kumegawa M., Hakeda Y. Regulation of receptor activator of NF-kappa B ligand-induced osteoclastogenesis by endogenous interferon-beta (INF-beta ) and suppressors of cytokine signaling (SOCS). The possible counteracting role of SOCSs- in IFN-beta-inhibited osteoclast formation. J. Biol. Chem. 2002, 277:27880-27886.
9. Hiruma Y., Kurihara N., Subler M.A., Zhou H., Boykin C.S., Zhang H., Ishizuka S., Dempster D.W., Roodman G.D., Windle J.J. A SQSTM1/p62 mutation linked to Paget's disease increases the osteoclastogenic potential of the bone microenvironment. Hum. Mol. Genet. 2008, 17:3708-3719.
10. Jin W., Chang M., Paul E.M., Babu G., Lee A.J., Reiley W., Wright A., Zhang M., You J., Sun S.C. Deubiquitinating enzyme CYLD negatively regulates RANK signaling and osteoclastogenesis in mice. J. Clin. Invest. 2008, 118:1858-1866.
11. Lucas G.J., Riches P.L., Hocking L.J., Cundy T., Nicholson G.C., Walsh J.P., Ralston S.H. Identification of a major locus for Paget's disease on chromosome 10p13 in families of British descent. J. Bone Miner. Res. 2008, 23:58-63.
12. Maruyama H., Morino H., Ito H., Izumi Y., Kato H., Watanabe Y., Kinoshita Y., Kamada M., Nodera H., Suzuki H., et al. Mutations of optineurin in amyotrophic lateral sclerosis. Nature 2010, 465:223-226.
13. Munitic I., Giardino Torchia M.L., Meena N.P., Zhu G., Li C.C., Ashwell J.D. Optineurin insufficiency impairs IRF3 but not NF-κB activation in immune cells. J. Immunol. 2013, 191:6231-6240.
14. Nagabhushana A., Bansal M., Swarup G. Optineurin is required for CYLD-dependent inhibition of TNFα-induced NF-κB activation. PLoS ONE 2011, 6:e17477.
15. Ralston S.H., Langston A.L., Reid I.R. Pathogenesis and management of Paget's disease of bone. Lancet 2008, 372:155-163.
16. Sudhakar C., Nagabhushana A., Jain N., Swarup G. NF-kappaB mediates tumor necrosis factor alpha-induced expression of optineurin, a negative regulator of NF-kappaB. PLoS ONE 2009, 4:e5114.
17. Takayanagi H., Kim S., Matsuo K., Suzuki H., Suzuki T., Sato K., Yokochi T., Oda H., Nakamura K., Ida N., et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-beta. Nature 2002, 416:744-749.
18. Westra H.J., Peters M.J., Esko T., Yaghootkar H., Schurmann C., Kettunen J., Christiansen M.W., Fairfax B.P., Schramm K., Powell J.E., et al. Systematic identification of trans eQTLs as putative drivers of known disease associations. Nat. Genet. 2013, 45:1238-1243.
19. Wild P., Farhan H., McEwan D.G., Wagner S., Rogov V.V., Brady N.R., Richter B., Korac J., Waidmann O., Choudhary C., et al. Phosphorylation of the autophagy receptor optineurin restricts Salmonella growth. Science 2011, 333:228-233.
20. Zeller T., Wild P., Szymczak S., Rotival M., Schillert A., Castagne R., Maouche S., Germain M., Lackner K., Rossmann H., et al. Genetics and beyond--the transcriptome of human monocytes and disease susceptibility. PLoS ONE 2010, 5:e10693.
21. Zhu G., Wu C.J., Zhao Y., Ashwell J.D. Optineurin negatively regulates TNFalpha- induced NF-kappaB activation by competing with NEMO for ubiquitinated RIP. Curr. Biol. 2007, 17:1438-1443.